ClinicalTrials.gov
public full text
Public Domain
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and relapsed and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: * To characterize the safety profile of SAR442257 * To characterize the pharmacokinetics (PK) profile of SAR442257 * To assess preliminary evidence of antitumor activity
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors#906675
- Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors#1170410
- Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors#1044906
- A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma#908800
- A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.#874917
Record · ID 1096325
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive